Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;39(11):1060-1065.
doi: 10.1002/phar.2330. Epub 2019 Oct 4.

Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series

Jeffrey J Cies  1   2   3 , Wayne S Moore 2nd  1 , Adela Enache  4 , Arun Chopra  1   5   6
Affiliations

Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series

Jeffrey J Cies et al. Pharmacotherapy. 2019 Nov.

Abstract

Objective: To describe the peramivir (PRV) pharmacokinetics in critically ill children treated for influenza A or B viral infections.

Design: Retrospective electronic medical record review of prospectively collected data from critically ill children receiving peramivir for influenza A or B viral infections in the pediatric intensive care unit (PICU).

Setting: A 189-bed, freestanding children's tertiary care teaching hospital in Philadelphia, PA.

Patients: Critically ill children admitted to the PICU who were infected with influenza between January 1, 2016 and March 31, 2018.

Interventions: None.

Results: Eleven patients, two females (18%) and nine males (82%), accounted for 24 peramivir samples for therapeutic drug management. The median age was 5 years (interquartile range 1.5-6.5 yrs) with a median weight of 16.4 kg (interquartile range 14-24 kg). Ten (91%) patients demonstrated a larger volume of distribution, 11 (100%) patients demonstrated an increase in clearance, and 11 (100%) patients demonstrated a shorter half-life estimate as compared with the package insert and previous pediatric trial data for peramivir. Eight (73%) patients tested positive for a strain of influenza A and 3 (27%) patients tested positive for influenza B; 4 of 11 (36%) patients tested positive for multiple viruses. All patients had adjustments made to their dosing interval to a more frequent interval. Ten (91%) patients were adjusted to an every-12-hour regimen and 1 (9%) patient was adjusted to an every-8-hour regimen. No adverse events were associated with peramivir treatment.

Conclusion: The pharmacokinetics of PRV demonstrated in this PICU cohort differs in comparison to healthy pediatric and adult patients, and alterations to dosing regimens may be needed in PICU patients to achieve pharmacodynamic exposures. Additional investigations in the PICU population are needed to confirm these findings.

Keywords: influenza; pediatric; peramivir; pharmacodynamic; pharmacokinetics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graph of individual peramivir (PRV) concentrations for 11 pediatric ICU patients treated for suspected or confirmed influenza infections
See this image and copyright information in PMC

References

    1. Peramivir (Rapivab®) [package insert]. Durham, NC: BioCryst Pharmaceuticals; December 2014.
    1. Drusano GL, Preston SL, Smee D, Bush K, Bailey K, Sidwell RW. Pharmacodynamic evaluation of RWJ‐270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once‐daily dosing. Antimicrob Agents Chemother 2001;45(7):2115–8. - PMC - PubMed
    1. Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012;56(1):369–77. - PMC - PubMed
    1. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010;54(11):4568–74. - PMC - PubMed
    1. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta‐lactam antibiotic doses sufficient for critically ill patients? Clinical Infect Dis 2014;58(8):1072–83. - PubMed

MeSH terms